



Urology Grand Rounds

Presented by

Yale School of Medicine, Department of Urology

“Management of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer”

Rachel Greenberg

Sub Intern from Albert Einstein

“Adjuvant Therapy in High Risk Localized RCC”

Daniel Segal

Sub Intern from SUNY-Downstate

“Resident Case Presentation”

Urology Resident

Date: Friday, September 1, 2017 7:30-8:30am

Location: Sterling Hall of Medicine
Beaumont Room (RM# SHML 221A)

Course Director/Host: Brian M. Shuch, MD

There is no corporate support for this activity

This course will fulfill the licensure requirement set forth by the State of Connecticut

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Greenberg: 1. Understand the updated definitions of BCG-unresponsiveness
2. Understand the current gold standard management and its limitations
3. Be aware of new therapies in development for BCG-unresponsive bladder cancer for patients unwilling or unable to undergo cystectomy
Segal: 1. Understand standard of care for high risk localized RCC management.
2. Understand the utility of adjuvant therapy for high risk localized RCC.
3. Understand the current literature around adjuvant therapy use for RCC.

- Residents: 1. Improve the quality of patient care
2. Review general urology concepts as well as rare/unusual cases
3. Improve care techniques and patient management

NEEDS ASSESSMENT

Greenberg: Currently, the gold standard of management of BCG-unresponsive non-muscle invasive bladder cancer is radical cystectomy. However, RC is a highly morbid procedure for which complications are unacceptable to some patients. Current research emphasizes the need for systemic or intravesical salvage therapy in patients who progress or recur after BCG therapy. In this lecture, we will review the literature on current management and explore therapies in development

Segal: The use of adjuvant therapy has been described for management in many types of cancer. However, Renal Cell Carcinoma has not yet had a defined standard of care for adjuvant therapy. There are recent results that have been published which help to redefine the role of adjuvant therapy in renal cell carcinoma which will be reviewed in this presentation

Residents: The goal of this conference is review unusual and teaching cases. The conference is designed to review basic as well as rare cases. Cases are analyzed and in a case review format and then there is a teaching session to review all important clinic aspects of the case with group discussion.

DISCLOSURES

Greenberg: None
Segal: None
Resident: None
Brian M. Shuch, MD, Course Director: None

TARGET AUDIENCE

The target audience are Urology attendings, residents, medical students and other healthcare providers

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.